monolabs INC. – Trademark Portfolio
Entity Type: 03
monolabs INC. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include MONO CODE, 4 BIRDIES GOLF, M'AMA NON M'AMA, and FOCUS ENERGY JELLY. The owner is based in Seoul.
11F, 537, Eonju-ro, Gangnam-gu
Seoul - , KR
Showing of trademarks Trademarks
Trademark Classifications
monolabs INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does monolabs INC. have?
monolabs INC. has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending.
What trademark classes does monolabs INC. file in?
monolabs INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are monolabs INC.'s most well-known trademarks?
monolabs INC.'s registered trademark portfolio includes well-known marks such as MONO CODE, 4 BIRDIES GOLF, M'AMA NON M'AMA, and FOCUS ENERGY JELLY. These are among 5 currently registered trademarks in the portfolio.
What is monolabs INC.'s trademark registration success rate?
monolabs INC. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 1 application is pending review.